Business
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of
About this update from Bioatla, Inc.
[{"type":"text","content":"SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day on Wednesday, December 13, 2023 at 10:00 AM ET. To register, click here. The event will feature Omid Hamid, MD (Cedars Sinai: The Angeles Clinic and Research Institute), who will review Phase 1 dose escalation trial results for BA3071, a novel conditionally and reversibly active antibody targeting CTLA-4. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment in combination with a PD-1 blocking agent. A live question and answer session will follow the formal presentation. About Omid Hamid, MD Omid Hamid, MD, is Chief, Translational Research and Immunotherapy, and Director, Melanoma Therapeutics at The Angeles Clinic and Research Institute. As the Director of the Melanoma Center and Phase I Immuno-Oncology Program, Dr. Omid Hamid works to ensure that patients receive access to the most up-to-date therapeutics. Most recently, in his role with the Phase 1 Developmental Therapeutics Program, Dr. Hamid has been instrumental in bringing new therapies from the investigational lab to the clinic for patient benefit. These therapies involve Immuno-Oncologic therapies such as PD-1 inhibitors (Keytruda, Nivolumab, Atezolizumab) and other checkpoint inhibitors, therapies against tumor angiogenesis, and targeted agents that block internal processes in tumor cell’s function (BRAF/MEK). Dr. Hamid’s research focus involves manipulation of a patient’s immune system to attack cancer cells and maintain continuously elevated levels of immunity and discovery of novel therapies. His research began in melanoma and has now extended into paradigm shifting trials for all cancers. Dr. Hamid is recognized nationally and internationally as a key opinion leader in Immuno-Oncologic Drug Development and Melanoma Therapeutics. Through his role as the Chief of Immunotherapy and Translational Research, patients at The Angeles Clinic have benefited from first-in-class, paradigm shifting drugs. Dr. Hamid was an investigator in the initial trials with Ipilimumab, Pembrolizumab, Nivolumab, Atezolizu...